US 12,274,696 B2
Methods of administering nalbuphine
Thomas Sciascia, Belmont, MA (US); and Shashank Rohatagi, New Haven, MA (US)
Assigned to Trevi Therapeutics, Inc., New Haven, CT (US)
Filed by Trevi Therapeutics, Inc., New Haven, CT (US)
Filed on May 9, 2022, as Appl. No. 17/739,848.
Application 17/739,848 is a continuation of application No. PCT/US2021/012734, filed on Jan. 8, 2021.
Claims priority of provisional application 63/014,306, filed on Apr. 23, 2020.
Claims priority of provisional application 62/959,701, filed on Jan. 10, 2020.
Prior Publication US 2022/0265640 A1, Aug. 25, 2022
Int. Cl. A61K 31/485 (2006.01); A61P 11/00 (2006.01)
CPC A61K 31/485 (2013.01) [A61P 11/00 (2018.01)] 30 Claims
 
1. A method of treating idiopathic pulmonary fibrosis (IPF) cough in a hepatically impaired patient, comprising:
(a) determining whether a patient is hepatically impaired; and
(b) orally administering a daily dose of about 9 mg to about 54 mg of an Equivalent Amount of Nalbuphine Free Base to a patient with severe hepatic impairment.